BIBX 1382, an EGFR inhibitor, and paroxetine, a serotonin reuptake inhibitor, are also among the potential therapeutic agents, along with doxorubicin, which has been repurposed as an anti-COVID-19 drug [41–43]. The gene discussed is EGFR; the disease is COVID-19.